Skip to: site menu | section menu | main content

Acomplia: The Wonder Slimming Drug

Information for consumers and GPs
Currently viewing: Acomplia » Home

Acomplia information resource

Navigation:

Latest News
Technical Info
Side Effects
Contraindications
Info for GPs
Disclaimer
Links

Articles:

Possible reason for Rimonabant Side Effects
Acomplia (Rimonabant) approved by Nice
Back to top
Back to top
This site does not represent and is not affiliated with Sanofi-Aventis, the manufacturers of Acomplia (Rimonabant).

Did you know?

Acomplia also reduces the desire for nicotine, but is not yet licensed as an aid to stopping smoking.

Acomplia is no longer licensed within the European Union, and has never been approved by the FDA in the US.

Acomplia is manufactured by the pharmaceutical company Sanofi Aventis. Its generic name is Rimonabant.

Acomplia will be known in the US as Zimulti.

The Acomplia capsule is red and yellow, and the recommended dose is one 20mg tablet once a day, before breakfast.

See our partner sites Xenical.me.uk and Reductil.me.uk

Acomplia Information Resource

acomplia tabletWelcome to the Acomplia information web site. If you, like millions of people around the world, struggle to keep your weight down, you cannot fail to have heard about Acomplia, purported to be the new wonder slimming drug. In clinical trials, over one year a third of patients lost 10% of their initial bodyweight, whilst nearly two thirds of patients on the trial lost over 5% of their initial bodyweight.

So that you can make an informed decision about this drug, this site has been created to provide a dedicated information resource about Acomplia, together with a forum where you can discuss your own experiences with the drug and slimming in general and learn from the experiences of others.

Sales of Acomplia have temporarily been suspended. See Latest News for further details.

buy now

Acomplia in the UK and EU

Acomplia has been approved for use within the EU and was available to patients in the UK from June 28th, 2006. The drug was approved by NICE (the National Institute for Health and Clinical Excellence) on June 24th, 2008.

Acomplia is likely to only be available on the NHS to patients who are clinically obese (they have a BMI in excess of 30) or overweight (they have a BMI in excess of 27) and exhibiting other clinical indications such as type II diabetes or an unsatisfactory blood lipid profile.

In all cases where Acomplia is prescribed on the NHS, the patients concerned must have already demonstrated that they have tried diet and exercise to lose weight, and they must try to maintain these efforts whilst taking the pill.

Acomplia in the US

Sanofi-Aventis applied for regulatory approval with the FDA in the US back in April 2005. However, in February 2006, the FDA stated that final approval would not be granted until some additional issues were satisfactorily resolved. It was not stated what these additional issues were. Given these delays, this drug is unlikely to get approval in the US anytime soon.

 

 

Back to top